CryoPort (CYRX) Stock Price, News & Analysis

Company Overview

CryoPort, Inc. (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms. These solutions enable uninterrupted maintenance of ultra-low temperatures during transit, while providing customers with transparency and compliance documentation. In addition to specialized containers for liquid nitrogen-based shipments, CryoPort offers on-demand logistics services, temperature excursion management and supply chain optimization tools via its cloud-based CryoPortal platform.

Leveraging a global network of logistics partners, CryoPort delivers services across North America, Europe, Asia-Pacific and Latin America. The company’s 24/7 operations and qualified service centers help streamline regulatory requirements and minimize risk for research institutions, pharmaceutical and biotechnology companies, contract research organizations and cell therapy manufacturers. CryoPort continues to expand its infrastructure and technology offerings to support the growing demand for advanced therapy supply chains worldwide.

Key Stats

• Today's Range: $15.05 to $15.42
• 50-Day Range: $14.02 to $16.57
• 52-Week Range: $7.51 to $16.89
• Volume: 111,733 shs
• Average Volume: 585,693 shs
• Market Capitalization: $769.13 million
• P/E Ratio: 11.30
• Dividend Yield: N/A
• Price Target: $16.38
• Consensus Rating: Moderate Buy

CryoPort Stock Analysis - MarketRank™

CryoPort scored higher than 53% of companies evaluated by MarketBeat, and ranked 482nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CryoPort has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for CryoPort is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

CryoPort has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CryoPort are expected to grow in the coming year, from ($0.85) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CryoPort is 11.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of CryoPort is 11.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 279.97.

Price to Book Value per Share Ratio

CryoPort has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.53% of the float of CryoPort has been sold short.

Short Interest Ratio / Days to Cover

CryoPort has a short interest ratio ("days to cover") of 3.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CryoPort has recently increased by 15.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CryoPort does not currently pay a dividend.

Dividend Growth

CryoPort does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.56

News Sentiment

CryoPort has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for CryoPort this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CYRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CryoPort insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,622,515.00 in company stock.

Percentage Held by Insiders

9.50% of the stock of CryoPort is held by insiders.

Percentage Held by Institutions

92.90% of the stock of CryoPort is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 8/05/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CYRX
• CIK: 1124524
• Web: www.cryoport.com
• Phone: (949) 470-2300
• Fax: 949-470-2306
• Employees: 1,186
• Year Founded: 1999

Price Target and Rating

• Average Price Target for CryoPort: $16.38
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +7.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.35
• Trailing P/E Ratio: 11.33
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $78.30 million
• Net Margins: 41.57%
• Pretax Margin: -19.13%
• Return on Equity: -7.92%
• Return on Assets: -4.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.09
• Quick Ratio: 2.00

Sales & Book Value

• Annual Sales: $182.94 million
• Price / Sales: 4.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.19 per share
• Price / Book: 1.66

Miscellaneous

• Outstanding Shares: 50,402,000
• Free Float: 45,614,000
• Market Cap: $770.65 million
• Optionable: Optionable
• Beta: 1.89